


serum



stools

HEV

Introduction, Virological aspects

Professor Françoise Lunel Fabiani, Virology Laboratory, CHU Angers, France

Virology




HEV : 30 to 34 nm RNA non enveloped virus

Hepeviridae viruses infect mammals, birds and fish

Strains infecting humans belong to the *Orthohepevirus* genus, species A

Species A , HEV, high variability
8 genotypes



- Only infect humans
- **Faecal-oral spread** via contaminated water
- Large **outbreaks**
- Brief, **self-limiting**
- Never chronic
- High mortality in **pregnancy** (25%)


- **Endemic** in animal species; eg, pigs and wild boar
- **Zoonotic** infections in humans
- **High-income countries**
- China: GT 4 most common
- S. America: GT 3 only

- Have only been reported in wild boar

- GT 7 identified in patient regularly consuming camel meat and milk
- Have since been identified in camels




Phylogenetic relationship of hepeviruses




* Namibia and Nigeria

Geographical distribution of HEV genotypes, *Khuro et al, WJG 2016*



HEV(G1 G2) 1st cause of acute hepatitis around the world






Figure 2. Modes of transmission of hepatitis E in developing countries. The settings for contamination of drinking water have been drawn in sketches, with epidemics reported in each case.

HEV genotype 1 and 2 – in developing countries - mode of transmission




HEV GT 3 and 4*: epidemiology

- Endemic in some developing countries, as well as most high-income countries
- Most common cause of acute viral hepatitis in many European countries
- Estimated that ≥ 2 million locally acquired HEV infections/year
 - Most as a result of zoonotic infection
 - Primary hosts are pigs
- HEV GT 3 and 4 tend to affect older males
 - Incidence varies between and within countries, and over time
 - Multiple 'hotspots' of HEV infection in Europe

* China and Taiwan

Natural History- HEV Diagnosis



New tests

- ✓ VIDAS® IgG et IgM anti-HEV, Biomérieux
 - ➔ Sensitivity IgG **0,56 U/ml**

		Infectious profile			
		Viremic phase	Post-viremic phase	No recent infection	Total
VIDAS®	Positif	83	42	2	127
Anti-HEV IgM	Négatif	2	29	301	332
Total		85	71	303	459
Performances		%	[IC95%]		
Positive concordance for viremic phase (acute phase)		97.65 %	[91.76 ; 99.71] %		
Positive concordance for post-viremic phase		59.15 %	[47.54 ; 69.83] %		
Negative concordance		99.34 %	[97.64 ; 99.92] %		



Abravanel, ESCV 2017

- ✓ VIRCLIA® / ALEGRIA® IgG et IgM anti-HEV, Orgentec


Performance ???



Direct Tests

✓ **HEV RNA:** PCR ou TMA, LoD 10-60 UI/ml

Abravanel, J Clin Microbiol 2013 ; Gallian, Transfusion 2017



Cobas 6800
Roche ®



Procleix Grifols ®,
Panther Hologic ®



Real Star HEV V2 Altona®
Quantitative

Qualitatives

✓ **HEV Ag**

specificity : **100 %**

diagnostic sensitivity : **91 %**

80 % immunocompetent

94 % l'immunosupressed

analytic sensitivity < PCR or TMA

Wen, J Clin Microbiol 2015 ; Trémeaux, J Clin Virol 2016 ; Behrendt, J Infect Dis 2016

Laboratory diagnosis of HEV infection



- Acute HEV infection can be diagnosed by detection of anti-HEV antibodies
 - IgM, IgG or both by enzyme immunoassays in combination with HEV NAT
- Serological testing relies upon detection of anti-IgM and (rising) IgG
- Molecular tests are needed to diagnose or confirm infection, especially in immunosuppressed patients

Infection status	Positive markers
Current infection - acute	<ul style="list-style-type: none">• HEV RNA• HEV RNA + anti-HEV IgM• HEV RNA + anti-HEV IgG*• HEV RNA + anti-HEV IgM + anti-HEV IgG• Anti-HEV IgM + anti-HEV IgG (rising)• HEV antigen
Current infection - chronic	<ul style="list-style-type: none">• HEV RNA (\pm anti-HEV) \geq3 months• HEV antigen
Past infection	<ul style="list-style-type: none">• Anti-HEV IgG

Diagnostic algorithm

